Journal
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
Volume 9, Issue 1, Pages 26-36Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756283X15618130
Keywords
anti-TNF agents; Crohn's disease; ustekinumab
Categories
Funding
- NIHR Biomedical Research Unit
- Nottingham University Hospitals NHS Trust
Ask authors/readers for more resources
Crohn's disease is an immune-mediated disease that results in panenteric chronic inflammation in genetically predisposed individuals exposed to an appropriate environment. The past two decades have witnessed the emergence of an important class of drugs known as anti-tumour necrosis factor (TNF) agents in the treatment of Crohn's disease. Unfortunately, the utility of these agents have been hampered by primary and secondary nonresponse in a significant proportion of patients. Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL) 12 and 23, is a novel pharmacotherapy for this patient cohort that offers an out-of-class option. It is approved for use in psoriasis and psoriatic arthritis, and has now been evaluated in phase II trials for moderate-to-severe Crohn's disease. We here review the published literature and describe a potential clinical role for its use in this disease cohort.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available